Once- versus twice-daily gentamicin dosing in neonates ≥ 34 weeks' gestation: Cost-effectiveness analyses

Pediatrics

Volumn 103, Issue 3, 1999, Pages 594-598

  Thureen, Patti J ^a,b   Reiter, Pamela D ^a   Gresores, Adrian ^c   Stolpman, Nancy M ^a   Kawato, Kerry ^a   Hall, Daniel M ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b CHILDREN S HOSPITAL   (United States)

^c Magella Medical Associates   (United States)

Author keywords

Cost effectiveness; Dosing; Drug concentrations; Gentamicin; Neonate; Once daily; Peak; Pharmacoeconomics; Tough

Indexed keywords

GENTAMICIN;

ANTIBIOTIC THERAPY; ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG BLOOD LEVEL; DRUG COST; HOSPITAL COST; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEWBORN SEPSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033059097     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.103.3.594     Document Type: Article

References (21)

1. Zaske DE. Aminoglycosides. In: Evans WE, Schentag J, Jusko W, eds. Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring. Vancouver, Canada: Applied Therapeutics, Inc; 1992:14-30
2. Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet. 1990;19:280-318
3. Lesko SM, Epstein MF, Mitchell AA. Recent patterns of drug use in newborn intensive care. J Pediatr. 1990;116:985-990
4. Barone MA. The Harriet Lane Handbook. St Louis, MO: Mosby-Year Book, Inc; 1996:545-546
5. Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. Hudson, OH: Lexi-Comp Inc; 1997:342
6. Kerr JR, Barr JG, Smyth ETM, O'Hare J. Technique for calculation of the true costs of antibiotic therapy. Eur J Clin Microbiol. 1992;11:823-827
7. Girgis NI, Sultan Y, Hammad O, Farid Z. Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children. Pediatr Inject Dis J. 1995;14:603-605
8. Hotchkies L, Grima DT, Hedayati S. The total process cost of parenteral antibiotic therapy beyond drug acquisition cost. Clin Ther. 1996;18: 716-725
9. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York, NY: Oxford University Press; 1997
10. Eddy MH. Cost-effectiveness analysis. JAMA. 1992;267:1669-1675
11. Keyes PS, Johnson CK, Rawlins TD. Predictors of trough serum gentamicin concentrations in neonates. Am J Dis Child. 1989;143:1419-1423
12. de Cos MA, Gomez-Ullate J, Gomez F, Armijo JA. Time course of trough serum gentamicin concentrations in preterm and term neonates. Clin Pharmacokinet. 1992;23:391-401
13. Hayani KC, Hatzopoulos FK, Frank AL, et al. Pharmacokinetics of once-daily dosing of gentamicin in neonates. J Pediatr. 1997;131:76-80
14. Skopnik H, Heimann G. Once daily aminoglycoside dosing in full term neonates. Pediatr Infect Dis J. 1995;14:71-72
15. Elhanan K, Siplovich L, Raz R. Gentamicin once-daily versus thrice-daily in children. J Antimicrob Chemotner. 1995;35:327-332
16. Massey KL, Hendeles L, Neims A. Identification of children for whom routine monitoring of aminoglycoside serum concentrations is not cost effective. J Pediatr. 1986;109:897-901
17. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997;39:677-686
18. Rotschafer JC, Zabinski RA, Walker KJ. Pharmacodyamic factors of antibiotic efficacy. Pharmacotherapy. 1992;112:64S-70S
19. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93-99
20. Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989;24:281-293
21. Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J Health Econ. 1993;12:459-467